Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide

P Iglesias1, J J Díez

  • 1Department of Endocrinology, Hospital General de Segovia, Madrid, Spain.

Insights

Long-term octreotide treatment normalized thyroid function and reduced tumor size in a patient with a TSH-secreting pituitary adenoma. This suggests octreotide may aid in surgical preparation for such rare pituitary tumors.

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Thyrotropin (TSH)-secreting pituitary adenomas are rare tumors.
  • Surgical resection is the primary treatment, but somatostatin analogues are used for unresectable or post-surgical cases.

Observation:

  • A 58-year-old man presented with a TSH-secreting pituitary adenoma causing hyperthyroidism.
  • Initial CT revealed a pituitary mass; hormonal evaluation showed elevated TSH and alpha subunit.
  • MRI confirmed a 2.0 x 1.8 x 1.7 cm pituitary mass.

Findings:

  • Subcutaneous octreotide administration led to reduced TSH levels.
  • 12 months of daily octreotide normalized TSH, free thyroxine, total triiodothyronine, and alpha subunit.
  • Tumor volume decreased from 2.0 x 1.8 x 1.7 cm to 1.6 x 1.7 x 1.4 cm after 6 months of octreotide therapy.

Implications:

  • Long-term octreotide therapy normalized thyroid function and reduced tumor volume pre-surgery.
  • Octreotide may be a valuable adjunct in preparing patients with TSH-secreting pituitary adenomas for surgery.